BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2879106)

  • 1. Goserelin therapy before surgery for uterine fibroids.
    Lumsden MA; West CP; Baird DT
    Lancet; 1987 Jan; 1(8523):36-7. PubMed ID: 2879106
    [No Abstract]   [Full Text] [Related]  

  • 2. Pretreatment with Zoladex improves surgery for uterine fibroids.
    Oncology (Williston Park); 1991 Jan; 5(1):94. PubMed ID: 1828691
    [No Abstract]   [Full Text] [Related]  

  • 3. Goserelin (Zoladex) in the treatment of fibroids.
    West CP; Lumsden MA; Baird DT
    Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():27-30. PubMed ID: 1532507
    [No Abstract]   [Full Text] [Related]  

  • 4. Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
    McClelland HR; Quinn AJ
    Ulster Med J; 1992 Apr; 61(1):51-5. PubMed ID: 1535743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids.
    Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA
    Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of patients with uterine myoma and its effectiveness].
    Vasil'chenko NP; Firichenko VI
    Akush Ginekol (Mosk); 1990 Feb; (2):7-10. PubMed ID: 2140246
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of fibroids.
    Altchek A
    Curr Opin Obstet Gynecol; 1992 Jun; 4(3):463-71. PubMed ID: 1535799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preoperative reduction of uterine leiomyoma by the GnRH-analog goserelin (zoladex)].
    Hackenberg R; Gesenhues T; Deichert U; Duda V; Sturm G; Schulz KD
    Geburtshilfe Frauenheilkd; 1990 Feb; 50(2):136-9. PubMed ID: 2138580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
    Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
    Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The place of GnRH agonists in the treatment of endometriosis and fibroids by advanced endoscopic techniques.
    Donnez J; Nisolle M; Grandjean P; Gillerot S; Clerckx F
    Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():31-3. PubMed ID: 1532508
    [No Abstract]   [Full Text] [Related]  

  • 11. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
    Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
    West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
    Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of LHRH analogue action in uterine fibroids.
    Shaw RW
    Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoladex (goserelin) in the treatment of benign gynaecological disorders: an overview of safety and efficacy.
    Miller RM; Frank RA
    Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():37-41. PubMed ID: 1532509
    [No Abstract]   [Full Text] [Related]  

  • 15. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical localization of epidermal growth factor receptor in leiomyomas from women treated with goserelin depot.
    Leone M; Cucuccio S; Venturini PL; Valenzano-Menada M; Messeni Leone M; De Cecco L
    Horm Metab Res; 1991 Sep; 23(9):442-5. PubMed ID: 1835956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month.
    Hackenberg R; Gesenhues T; Deichert U; Duda V; Schmidt-Rhode P; Schulz KD
    Eur J Obstet Gynecol Reprod Biol; 1992 Jul; 45(2):125-9. PubMed ID: 1386817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The management of leiomyoma uteri by GnRH analogues.
    Giorgino FL; Cetera C
    Clin Exp Obstet Gynecol; 1991; 18(2):137-43. PubMed ID: 1833095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of treatment with LHRH analogue Zoladex on binding of oestradiol, progesterone and epidermal growth factor to uterine fibromyomata.
    Baird DT; Bramley TA; Hawkins TA; Lumsden MA; West CP
    Horm Res; 1989; 32 Suppl 1():154-6. PubMed ID: 2533146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of peri-menopausal women: potential long-term therapy with a depot GnRH agonist combined with hormonal replacement therapy.
    Maheux R; Lemay A
    Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():13-7. PubMed ID: 1532506
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.